Transitions in Care for Patients with Cancer


Patients with cancer often transition between medical providers and institutions when they are being diagnosed with cancer and receive cancer treatment. These transitions are thought to have a negative effect on patient health. However, little is known about how patients with cancer are affected by such transitions. Our study will look at how cancer care can be better during transitions between medical providers and institutions. To do this, we want to look at the effect that the transitions have on patient’s health and the medical system by asking patients and medical providers about their experiences. We will create a list of areas where care can be improved based on the perspectives of patients and medical providers and we will ask a group (including researchers, decision-makers, medical providers, and patients) to identify the areas of care that are the most important to change.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 100

Accepts healthy participants: Yes

Inclusion criteria:

1. Adult, above 18 years old
2. Patients that have been diagnosed with cancer
3. Patients can be at any stage of cancer care (from diagnosis to survivorship)
4. Patients who have experienced a move or transition between medical providers or centers in Alberta
5. A medical professional who provides medical care to patients with cancer, at any stage of their cancer care

Exclusion criteria:

1. Patients younger than 18 years old
2. Patients who have not had cancer
3. Patients who have not moved or transitioned their care between medical care providers or centers
4. Patients who received their cancer care outside of Alberta
5. Medical providers that have not cared for patients with cancer


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Recruitment will be directed to the Principal Investigator of this study.

Principal investigator:

Khara Marissa Sauro

Clinical trial: